Abstract
Loteprednol etabonate is a corticosteroid which is the product of ‘soft drug’ design (synthesis of a compound that undergoes predictable metabolism to inactive metabolites after its therapeutic effects have been expressed at or near the site of application). It has been developed as a topical treatment for ocular inflammation.
Loteprednol etabonate is designed to be rapidly converted to inactive and nontoxic metabolites, thus minimising systemic adverse effects. The concentration of the drug in plasma from 10 healthy volunteers who received ocular loteprednol etabonate at therapeutic or supratherapeutic dosages was below the limit of detection.
In 2 double-masked, placebo-controlled studies, loteprednol etabonate 0.5% 4 times daily (1 drop/eye) for 2 weeks was more effective than placebo in relieving moderate to severe postoperative ocular inflammation after cataract surgery. The same regimen was also effective when administered for up to 6 weeks in 3 double-masked placebo-controlled studies in patients with moderate or severe contact lens-associated giant papillary conjunctivitis. Data from 2 double-masked placebo-controlled studies indicate that loteprednol etabonate 0.2% (1 drop/eye 4 times daily for 2 weeks) is effective in patients with moderate to severe seasonal allergic conjunctivitis. Furthermore, a single placebo-controlled trial has shown that loteprednol etabonate 0.5% has prophylactic efficacy in patients with a history of seasonal allergic conjunctivitis.
Ocular loteprednol etabonate was well tolerated, both locally and systemically, in clinical trials reported to date. Elevated intraocular pressure (IOP) is possible after ocular administration of the drug but is infrequent overall: only 1.7% of 901 patients or volunteers who received loteprednol 0.2 or 0.5% for ≥ 28 days had a clinically significant increase (≥ 10mm Hg) in IOP. Unlike prednisolone acetate, loteprednol etabonate did not significantly increase IOP from baseline in a small randomised crossover study in known steroid responders. There were no serious or unexpected treatment-related ocular adverse events in patients receiving loteprednol etabonate in clinical trials. The potential for cataract formation or glaucoma after long term treatment is unknown.
Thus, loteprednol etabonate can reduce ocular inflammation caused by cataract surgery, seasonal allergic conjunctivitis or contact lens wear. The benign tolerability profile of loteprednol etabonate, in particular its low propensity to cause elevated IOP (when used in the short term) is an attractive characteristic. However, the place of loteprednol etabonate in clinical practice cannot be properly assessed until direct efficacy comparisons with other active treatments are available.
Similar content being viewed by others
References
Howes JE. Development of soft drugs for ophthalmic use. In: Reddy IK, editor. Ocular therapeutics and drug delivery: a multidisciplinary approach. Lancaster (PA): Technomic Publishing Company, Inc., 1996: 363–74
Bodor N. Design of novel soft corticosteroids. Curr Probl Dermatol 1993; 21: 11–9
Bodor N. Designing safer ophthalmic drugs by soft drug approaches. J Ocul Pharmacol 1994; 10(1): 3–15
Lee HL, Iimoto DS, Takemoto KA. Subcellular distribution of esterases in the bovine eye. Curr Eye Res 1982/1983; 2(12): 869–76
Lee VHL, Smith RE. Effect of substrate concentration, product concentration, and peptides on the in vitro hydrolysis of model ester prodrugs by corneal esterases. J Ocul Pharmacol 1985; 1(3): 269–78
Druzgala P, Hochhaus G, Bodor N. Soft drugs—10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 1991 Feb; 38: 149–54
Abelson M, Howes J, George M. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 1998 (In press)
Reddy IK, Khan MA, Wu W-M, et al. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. J Ocul Pharmacol Ther 1996; 12(2): 159–67
Druzgala P, Wu W-M, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991 Oct; 10: 933–7
Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1997; 14(2): 153–8
Hochhaus G, Chien L-S, Ratka A, et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992 Dec; 81: 1210–5
Bodor N, Wu W-M, Murakami T, et al. Soft drugs 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995 Jun; 12: 875–9
Bodor N, Loftsson T, Wu W-m. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992 Oct; 9: 1275–8
Wu W-M, Murakami T, Angel S, et al. Pharmacokinetics, metabolism and excretion of a soft corticosteroid, loteprednol etabonate [abstract]. Pharm Res 1992 Oct; 9(Suppl): S295
Wu W-M, Bodor N. Metabolism and excretion of loteprednol etabonate, a soft corticosteroid, in rats [abstract]. Pharm Res 1994 Oct; 11Suppl.: 364
Stewart R, Horwitz B, Howes J, et al. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. J Cataract Refract Surg 1998 (In press)
The Loteprednol Etabonate Post-operative Inflammation Study Group 2. A double-masked,placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of post-operative inflammation. Ophthalmology 1998 (In press)
Dell SJ, Shulman DG, Lowry GM, et al. Acontrolled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1997 Jun; 123: 791–7
Dell SJ, Lowry GM, Northcutt JA, et al. Arandomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol 1998 Aug; 102(2): 251–5
Shulman DG, Lothringer HL, Rubin JM, et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1998 (In press)
Bartlett JD, Howes JF, Ghormley NR, et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993 Apr; 12: 313–21
Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol 1997 Apr; 123: 455–64
Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J 1997 Jan; 23: 31–6
Raizman M. Corticosteroid therapy of eye disease: Fifty years later. Arch Ophthalmol 1996; 114(8): 1000–1
Novack GD, Howes J, Crockett RS, et al. Change in intraocular pressure during chronic use of loteprednol etabonate. J Glaucoma 1998. In press
Bartlett JD, Horwitz B, Laibovitz R, et al. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993 Summer; 9: 157–65
Bausch & Lomb Pharmaceuticals Inc. Lotemax™ loteprednol etabonate ophthalmic suspension, 0.5%. Prescribing information. Tampa (FL), USA, 1998
Bausch & Lomb Pharmaceuticals. Alrex™ loteprednol etabonate ophthalmic suspension, 0.2%. Prescribing information. Tampa (FL), USA, 1998
Ciprandi G, Buscaglia S, Canonica GW. Management of allergic conjunctivitis. Clin Immunother 1996 May; 5: 374–91
Allansmith MR. Giant papillary conjunctivitis. J Am Optom Assoc 1990; 61(6) Suppl.: S42–46
Allansmith MR, Ross RN, Greiner JV. Giant papillary conjunctivitis: diagnosis and treatment. In: Dabezies Jr OH, Cavanagh HD, Farris RL, et al., editors. Contact lenses: the CLAO guide to basic science and clinical practice. 2nd ed. Boston: Little, Brown and Company, 1984: 43.1–43.17
Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986 Jan/Feb; 30(4): 229–44
Asbell PA, Torres MA. Therapeutic dilemmas in external ocular diseases. Drugs 1991 Oct; 42: 606–15
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Noble, S., Goa, K.L. Loteprednol Etabonate. BioDrugs 10, 329–339 (1998). https://doi.org/10.2165/00063030-199810040-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-199810040-00007